Radiation induced thyroid dysfunction is usually underestimated in patients with breast cancer who had supraclavicular irradiation (RT). In the present study, a total of 28 patients with breast cancer received supraclavicular RT were evaluated focusing on radiation dose-volume factors in relation to thyroid function. Thyroid function tests, including serum thyroid stimulating hormone, free thyroxine, free triiodothyronine, were analyzed prior to RT and 3, 6, 9, 12, 18 and 24 months after RT. Based on each patient's dose volume histogram (DVH), total volume of the thyroid, mean radiation dose the thyroid and percentages of thyroid volume which received radiation doses 10-50 Gy (V10-V50) were considered for statistical analysis. The median follow-up time was 25 months (range, 12.3-36 months). Of 28 patients 6 (21%) were diagnosed with hypothyroidism (HT). The median time to the development of HT was 9 months (range: 3-18 months). Mean thyroid dose was 31 Gy (19-48 Gy) and mean thyroid volume was 32 cc (12-64 cc). We found that V20 (OR= 10, 95% CI= 1.15-86.88, p= 0.05), V30 (OR= 10, 95% CI= 1.15-86.88, p= 0.05) and V40 (OR= 21, 95% CI= 1.61-273.34, p= 0.02) and mean thyroid dose ≥36 Gy (OR= 10, 95% CI= 1.15-86.88) (p= 0.05), had a significant impact on development of HT. Moreover, significant elevation was observed in mean TSH level between baseline (1.85±1.47 mIU/L) and at 6 months (3.80±7.42 mIU/L), (p= 0.003). Supraclavicular RT in patients with breast cancer appear to amplify the risk of HT. We believe further investigations in larger cohort are required to confirm our results.
INTRODUCTION
Thyroid dysfunction is a well-known late effect after radiotherapy (RT) to the neck region in patients with head and neck cancers. [1] [2] [3] [4] In such patients, the whole gland is usually located with in the high-dose level of radiation fields but little has been studied in breast cancer patients receiving RT to the supraclavicular field that involves part of thyroid gland inevitably included in the RT portals.
Of the different types of radiation-induced thyroid dysfunction, subclinical hypothyroidism (HT) is the most common, this is followed by clinical HT. Subclinical HT is defined biochemically as a normal free serum thyroxine hormone (fT4) level in the presence of an elevated thyroid stimulating hormone (TSH), with no clinical symptoms, whereas clinical HT is characterized by a high serum TSH level and low fT4 level, in which patient may present with clinical sypmptoms such as weight gain, fatigue, slow mentation and cold intolerance. Hypothyroidism after RT develops at a median interval of 1.4-1.8 years, but it has been reported even 3 months or 20 years after RT.
2,3,5
The tolerance dose of the thyroid gland has not been definitively determined. 6 With conventional fractionation, the critical absorbed dose for radiation induced HT has been estimated to vary between 26 to 40 Gy. 7, 8 In the Quantitative Analysis of Normal Tissue Effects in the Clinic (QUANTEC) report, dose-volume data for HT were not included. 9 Some authors suggest that the percentage of thyroid volume receiving ≥30 Gy (V30) is a possible predictor of HT. 10, 11 To date, a clear threshold dose or dose-volume factors for the development of radiation induced HT has not yet been determined.
This study was undertaken to investigate radiation induced thyroid dysfunction in patients with breast cancer receiving RT to the supraclavicular field in relation to total dose and irradiated volume of the thyroid gland by assessing thyroid function before and regular intervals after RT.
MATERIALS AND METHODS

Patients and Characteristics
Between October 2010 and December 2012 a total of 28 patients with breast cancer received supraclavicular irradiation were evaluated. Exclusion criteria were: 1) patients with primary thyroid disease, 2) thyroid surgery 3) previous RT at another facility that might have included the hypothalamic-pituitary axis or lower neck nodes.
Radiotherapy
All patients treated with 3 or 4-field 3D conformal RT (3D-CRT) in which the target volume included the breast or the chest wall and the ipsilateral supraclavicular field (Figure 1-3) . The RT planning was based on computerized tomography (CT) scans covering the region from cricoid cartilage to 5 cm below the clinically marked inferior port edge. CT slice thickness and pitch was 0.5 cm. The clinical target volume, both lungs, heart, contralateral breast and the thyroid gland were delineated by the same radiation oncologist. Treatment planning and dose calculation were performed using the Eclipse (version 10) or Precise Plan planning system. Treatment delivered with Varian Clinac DHX or Electa Synergy Platform linear accelerator with the photon beams energy was 6 MV and/or 18 MV. The total dose of 50 Gy in 25 fractions was given to the breast/chest wall and the ipsilateral supraclavicular field. Nine of the patients received an additional 10 Gy to the tumor bed. Based on each patient's dose volume histogram (DVH), total volume of the thyroid, mean radiation dose to the thyroid and percentages of thyroid volume which received radiation doses 10-50 Gy (V10-V50) were considered for statistical analysis.
Thyroid Function Tests
Thyroid function tests consisting of a baseline serum thyroid stimulating hormone (TSH, reference range 0.34-5.60 mIU/L), free triiodothyronine (fT3, reference range 3.8-6 pmol/L), free thyroxine (fT4, reference range 7-16 pmol/L were analyzed prior to RT and every three months the first year and then 18 month, and finally 24 month after RT. A diagnosis of HT was based on TSH value grater than the maximum value of laboratory range and/or fT3 and/or fT4 values lower than the minimum value of laboratory range, regardless of whether any symptom was present.
Statistical Analysis
Statistical analysis was performed with a Statistical Package for the Social Scienses for Windows (SPSS, version 11.5, Chicago, IL). All values are expressed 
RESULTS
The median follow-up time was 25 months (range, 12,3-36 months). Demographic information for all patients is summarized in Table 1 .
Of 28 patients 6 (21%) were diagnosed with hypothyroidism (HT), 2 (7%) cases had subclinical HT and 4 (14%) cases had clinical HT. The median time to the development of HT was 9 months (range, 3-18 months). Patients who had HT were also screened for antithyroglobulin and antimicrosomal antibodies, antibody titers did not positive in any of these patients. Patients diagnosed clinical HT referred to endocrine department and they received thyroid hormone replacement therapy. Table 2 shows the mean (±SD) for each thyroid function test before and after completion of RT, 3, 6, 9, 12, 18 and 24 months, respectively. Mean baseline TSH level was 1.85±1.47 mIU/L. The difference in TSH level between baseline and 3 months (mean TSH: 2.01±1.65 mIU/L, p= 0.28) was not significant. However, significant elevation was observed at 6 months (mean TSH: 3.80±7.42 mIU/L, p= 0.003). There was a significant decrease in the mean fT4 levels after the third month on completion of RT compared with baseline levels (p= 0.004) and then relatively become stable. Mean fT3 level showed steady throughout the study period.
Mean thyroid dose, volume and percentage of thyroid gland volume absorbing V10-50 were analyzed acording to DVHs. Mean thyroid dose was 31 Gy (19-48 Gy) and mean thyroid volume was 32 cc (12-64 cc). 
DISCUSSION
Our results demonstrated that overall incidence of HT was 21% in patients with breast cancer who had supraclavicular RT. The median time to the development of HT was 9 months (range, 3-18 months). Radiation induced HT in patients with breast cancer has been investigated in only a few studies. [12] [13] [14] According to these studies, the incidence of HT varies 6% and 21% similar to our study. Bruning et al. concluded that HT was significantly more frequent in patients with breast cancer who had received RT to supraclavicular field to non-irradiated breast cancer patients.
14
Our best of knowledge, only a few investigators have performed clinical DVHs analysis for thyroid dysfunction after RT. 8, 10, [15] [16] [17] [18] Most of theses studies concerned head and neck cancer patients treated with RT doses higher than those used in RT for breast cancer. In these studies, different dose-volume parameters were used and no baseline assessments of thyroid function were available. Additionally, there was no consistency with regard to follow-up protocol at specified time points. In this study TSH, fT4 and fT3 were monitored prior to RT and regular intervals after RT with a standardized follow-up protocol. We found V20-40 (thyroid volume receiving over 20-40 Gy) and mean thyroid dose ≥36 Gy had a significant impact on development of HT. Yoden et al. also used DVHs to evaluate the correlation between percentage of the thyroid gland volume absorbing a defined dose and thyroid function. 11 They found that V10, V20 and V30 have significant impact on the peak level of serum TSH and seemed to be possible risk factor for HT. Similarly, Cella et al. reported the V30 was the only independent predictive factor for HT. 10 In other 2 studies, that DVHs and percentage of thyroid gland volume absorbing V10-60, Dmin, Dmax were determined. Both of the study revealed that this dosevolume parameters were not associated with HT. 15, 18 However, recent studies published a normal tissue complication probability (NTCP) model based on mean thyroid dose and thyroid volume for radiation induced HT in patients with head and neck cancer. 19, 20 According to these studies, thyroid gland volume and mean thyroid dose were the only independent risk factors for HT. We think that, these NTCP model studies need to support more clinical data.
In our study, mean TSH levels did not change in the first 3 months however after 6 months significantly higher than baseline levels. Additionaly mean fT4 levels showed decreasing at 3 months and then relatively become stable. These finding implied that the majority of change in thyroid function within 6 months after RT. Other reports similarly indicate that radiation-induced changes in thyroid function initially manifested within 3 to 6 months after RT. [21] [22] [23] The time to development of HT has not been con- International Journal of Hematology and Oncology clusively defined. Prospective trials have been conducted in an attempt to answer this question. 1, 5, [24] [25] [26] As stated in these trial, the median time to development of HT appears to range from 1.4 years to 1.8 years.
2,5 Latency has been observed as soon as 2 to 3 months and as late as 20 years. 2, 3, 23 In our study the median follow-up time was 25 months (range, 12,3-36 months) and the median time to the development of HT was 9 months (range: 3-18 months). Some of the studies suggest longer follow up period after RT because of an increase in the cumulative incidence beyond two years of completion of RT. Mercado et al. described the incidence of HT was 48% at 5 years and 67% at 8 years.
5 Results of our analysis also produced correlation between follow-up duration and incidence of HT that 14% at 12 months and 21% at 24 months. In our institute, we continue to monitor all patients who had neck irradiation routinely for thyroid function in their follow-up visit.
The impact of the chemotherapy and endocrine treatments to the development of HT in breast cancer patients have been showed in several studies. 12, 14, 21, 27 However, some studies suggest that addition of chemotherapy does not increase the risk of development of HT. 4, 5, 25, 28 İn review, Jereczek-Fossa stated that the impact of chemotherapy and endocrine treatments on the risk of HT is still controversial. 6 In our study, all of our patients received both chemotherapy and RT so we could not evaluate the impact of each treatment separately.
Different treatment techniques may cause higher RT doses to thyroid gland if the dose is not constrained.
Diaz et al. reported on an apparent higher incidence and shorter latency of post-treatment HT with intensity modulated RT (IMRT) compared with 3D-CRT. 15 This was contributed to higher dose to the thyroid gland with IMRT reference to 3D-CRT. Contouring the thyroid gland as an IMRT avoidance structure, resulted in a significantly lower median thyroid gland dose as compared with 3D-CRT. In our study all patients treated with 3 or 4 field 3D-CRT.
We observed a marked increase in the development of HT in patients with breast cancer following supraclavicular RT. Our finding implied that the majority of changes in thyroid function initially manifested within 3 to 6 months after RT. We found mean thyroid dose ≥ 36 Gy and V20-40 had a significant impact on the development of HT. Because of the risk of HT, in such patients, thyroid function should be evaluated periodically. However, we believe further investigations in larger cohort are required to confirm our results.
